JUNS Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
24.2K
+30.0%
18.7K
-14.4%
21.8K
0
0
Cost of Revenue
3.2K
-27.1%
4.4K
+3.1%
4.2K
0
0
Gross Profit
21.1K
+47.4%
14.3K
-18.6%
17.6K
0
0
Operating Expenses
2.8M
+39.8%
2.0M
-30.0%
2.8M
+23.0%
2.3M
+1.4%
2.3M
R&D
600.4K
+46.1%
411.0K
+841.0%
43.7K
-94.7%
816.7K
+7.5%
759.4K
SG&A
2.2M
+38.1%
1.6M
-43.7%
2.8M
+88.0%
1.5M
-1.7%
1.5M
Operating Income
-2742945
-39.7%
-1963000
+30.1%
-2808785
-22.3%
-2297053
-1.4%
-2264880
EBITDA
-2551803
-43.8%
-1773959
+32.2%
-2615543
-24.3%
-2103811
-1.5%
-2073739
Net Income
-2274397
-10.3%
-2061958
+19.9%
-2575031
-12.5%
-2288034
-1.6%
-2252965
EPS (Basic)
$-4.08
+9.3%
$-4.50
+11.1%
$-5.06
+3.6%
$-5.25
-3.1%
$-5.09
EPS (Diluted)
$-4.08
+9.3%
$-4.50
+11.1%
$-5.06
+3.6%
$-5.25
-3.1%
$-5.09
Shares (Diluted)
557.6K
+18.6%
470.1K
-7.7%
509.2K
+12.2%
453.9K
+2.6%
442.4K
Jupiter Neurosciences (JUNS) โ€” Financials